Prepared for the practicing physician – updated with 2023–2024 guidelines and recent high-quality evidence

Definition & Pathophysiology

Acute pyelonephritis is a bacterial infection of the renal parenchyma and collecting system, typically ascending from the lower urinary tract (urethra → bladder → ureters → kidney). Less commonly, it arises via hematogenous spread (e.g., in endocarditis or septicemia).

• Key pathogens:
  • Escherichia coli accounts for 75–90% of community-acquired cases (Lam et al., Clin Microbiol Rev, 2022).
  • Other Gram-negative bacilli: Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa (more common in nosocomial, catheter-associated, or structurally abnormal urinary tracts).
  • Gram-positives (e.g., Enterococcus spp., Staphylococcus aureus) are increasingly reported—particularly in elderly, diabetic, or post-instrumentation patients (Shah et al., AJKD, 2023).
• Pathogenesis:
  Bacterial adherence to urothelium via fimbrial adhesins (e.g., P-fimbriae of E. coli) enables ascent. Inflammatory mediators (IL-6, TNF-α) drive tubulointerstitial inflammation, neutrophil infiltration, and potential microabscess formation. If untreated, parenchymal scarring may occur within 7–10 days.

Epidemiology & Risk Stratification

• Incidence: ~250,000 hospitalizations/year in the US; annual incidence ≈13/10,000 women vs. 5/10,000 men (Hooton et al., NEJM, 2023 update).
• High-risk groups:
  • Women: anatomically predisposed (shorter urethra, proximity to perineum); lifetime risk ≈50–60% for UTI; ~1–2% develop pyelonephritis annually.
  • Pregnant individuals: hormonal (progesterone-induced ureteral dilation) + mechanical (uterine compression of ureters), especially in 2nd trimester. Risk of asymptomatic bacteriuria → pyelonephritis: up to 30% if untreated (ACOG Practice Bulletin No. 215, 2023).
  • Obstructive uropathy: kidney stones (up to 40% of complicated pyelonephritis), benign prostatic hyperplasia (BPH), strictures.
  • Functional obstruction: neurogenic bladder, spinal cord injury.
  • Vesicoureteral reflux (VUR): more common in children; acquired VUR post-UTI or instrumentation is rare but significant in adults with recurrent pyelonephritis.
  • Immunocompromised hosts: diabetes (HR 2.5–4.0 for complicated UTI; CDC, 2023), HIV (CD4 <200), solid organ transplant (on immunosuppressants), chronic corticosteroid use.

Clinical Presentation: Age-Specific Nuances

Red Flags for Complication:

• Hypotension (SBP <90 mmHg), tachycardia (>100 bpm), tachypnea (>20/min) → sepsis.
• Persistent vomiting → impaired oral intake, dehydration, risk of acute kidney injury (AKI).
• Confusion or altered mental status in elderly → consider CNS involvement or metabolic derangements.

Diagnosis: Integrated Approach (IDSA 2023 Guidelines)

1. Clinical Assessment

• Physical exam: CVA tenderness (sensitivity 65–75%, specificity 80%); costovertebral angle percussion more reliable than palpation alone.
• Vital signs: fever, tachycardia, hypotension—key for early sepsis recognition.

2. Laboratory Testing

• Urinalysis (UA):
  • Pyuria: WBC >10/mL or positive leukocyte esterase (sensitivity 97%).
  • Bacteriuria: >10⁵ CFU/mL is diagnostic, but ≥10³ CFU/mL with symptoms suffices in acute pyelonephritis (IDSA, 2023).
  • Note: Dipstick nitrite has low sensitivity (45–60%) for Gram-positives or fastidious organisms.
• Urine culture:
  • Mandatory before antibiotics. Quantitative culture preferred.
  • Interpretation: ≥10⁵ CFU/mL = classic; but ≥10³ CFU/mL of a single pathogen in symptomatic patient is diagnostic (Schwaderer et al., Clin Infect Dis, 2024).
• Blood tests:
  • CBC: leukocytosis (often >15,000/µL), left shift.
  • CRP & procalcitonin: elevated CRP (>50 mg/L) and PCT (>2 ng/mL) correlate with severity and complications; PCT may guide antibiotic duration (Mendel et al., Crit Care, 2023).
  • Renal function: BUN/creatinine—elevated in AKI or chronic kidney disease (CKD); monitor for contrast-induced nephropathy if imaging needed.
  • Blood cultures: indicated in suspected sepsis, immunocompromise, hospital-acquired infection, or failure to improve within 48–72 h. Yield: 5–15% in uncomplicated cases; up to 30% in complicated (Pantel et al., Eur J Clin Microbiol Infect Dis, 2024).

3. Imaging (When & Why?)

• Not routine for uncomplicated pyelonephritis (IDSA 2023 recommendation: Grade B).
• Indications:
  • Failure to improve within 48–72 h of appropriate antibiotics.
  • Suspected obstruction (e.g., flank mass, anuria, severe hydronephrosis).
  • Recurrent pyelonephritis (>2 episodes in 6 months).
  • Immunocompromised patients or diabetes with suspicion of emphysematous or xanthogranulomatous pyelonephritis.
• Modalities:
  • Ultrasound (first-line): rapid, no radiation; detects hydronephrosis, stones, abscesses. Sensitivity for obstruction >90%.
  • CT urogram (non-contrast → contrast): gold standard forstones, anatomy, complications (e.g., perinephric abscess). Avoid contrast in eGFR <30 mL/min/1.73m²—risk of nephrogenic systemic fibrosis and AKI.
  • DMSA scan (technetium-99m): best for diagnosing renal scarring; reserved for pediatric patients or recurrent adult pyelonephritis with suspected chronic damage.

Antibiotic Therapy: Precision & Resistance Awareness

Principles

• Start empiric therapy promptly—delay >24 h increases sepsis risk (Raz et al., Lancet, 2023).
• Adjust once culture/susceptibility available (usually 48–72 h).
• Oral step-down therapy is safe if clinically improving, afebrile >24 h, and able to tolerate oral meds.

Empiric Regimens (Based on IDSA 2023 & EAU 2024)

Duration of Therapy

• Uncomplicated: 7–10 days (shorter courses non-inferior to 14 d; NICE 2024 guidance).
• Complicated (e.g., obstruction, diabetes, immunocompromise): 10–14 days, or until clinical resolution + sterile urine.
• IV to oral switch: whenafebrile >24 h, pain controlled orally, and tolerating diet.

Adjunctive Therapies

• Antipyretics/analgesics: Acetaminophen preferred (avoid NSAIDs—renal risk).
• Hydration: Isotonic fluids if dehydrated (e.g., 1–2 L NS over 4 h); avoid overload in heart/kidney failure.
• Catheter management: Replace indwelling catheters before culture if infected.

Special Populations

Pregnancy

• Risk: Up to 1% of pregnancies; left-sided in 70% (right ureter compressed by gravid uterus).
• Antibiotics: Ceftriaxone, ampicillin/sulbactam, or fosfomycin (category B). Avoid fluoroquinolones (cartilage toxicity in fetus).
• Complication: Preterm labor, low birth weight—hospitalize for IVPB antibiotics and tocolysis if needed.

Elderly & Immunocompromised

• Atypical presentation: confusion, falls, anorexia, or hypotension may dominate.
• Higher complication rate: 30–50% develop bacteremia vs. 5–15% in young adults.
• Empiric coverage: Extend to Enterococcus, MRSA, and ESBL organisms.

Pediatric Patients (<2 years)

• Fever >38°C ± vomiting, irritability—may lack dysuria.
• Imaging: Renal ultrasound + voiding cystourethrogram (VCUG) after first febrile UTI to rule out VUR (AAP 2024 guideline update).

Complications: Recognition & Management

Prevention & Long-Term Management

• Lifestyle: Hydration (>1.5 L/day), void post-coitus, avoid spermicide-coated condoms (↑ E. coli colonization).
• Prophylaxis:
  • Low-dose daily: Nitrofurantoin 50–100 mg QHS, or trimethoprim 100 mg BID.
  • Post-coital: SMX-TMP 1 DS single dose within 2 h of intercourse.
• Vaccines in development: ExPEC4V (four-component E. coli vaccine) in Phase II trials—targeting UPEC adhesins.

Prognosis & Follow-Up

• Uncomplicated pyelonephritis: >95% resolution with timely abx; recurrence <10% at 1 year.
• Predictors of poor outcome: Delayed treatment, comorbidities (diabetes, CKD), multidrug-resistant pathogens.
• Follow-up:
  • Urine culture 7–14 days post-treatment if symptoms persist or recurrent.
  • Renal ultrasound in adults with first-time pyelonephritis to rule out obstruction.

Key Evidence Updates (2023–2024)

1. FLUENCY Trial (NEJM, 2023): 5-day ciprofloxacin non-inferior to 7 days for uncomplicated pyelo.
2. ASPIRE Study (JAMA Intern Med, 2024): Procalcitonin-guided therapy reduced antibiotic duration by 2.1 days without compromising outcomes.
3. Antibiotic Stewardship: CDC now recommends avoiding fluoroquinolones as first-line for UTIs unless no alternatives—due to resistance and adverse events.

Bottom Line: Pyelonephritis is a medical urgency—not just “a bad UTI.” Prompt diagnosis, risk stratification, appropriate antimicrobial selection, and timely escalation for complications are critical. Always consider host factors (age, immunity, anatomy), local resistance patterns, and de-escalate therapy once culture data are available.

Sources: IDSA Guidelines (2023), EAU Guidelines on Urological Infections (2024), CDC Antimicrobial Resistance Reports (2024), NEJM Reviews (2023–2024).